Deric Park to Antineoplastic Agents
This is a "connection" page, showing publications Deric Park has written about Antineoplastic Agents.
Connection Strength
0.759
-
Modular peptide-functionalized gold nanorods for effective glioblastoma multicellular tumor spheroid targeting. Biomater Sci. 2018 May 01; 6(5):1140-1146.
Score: 0.287
-
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016 12; 130(3):571-579.
Score: 0.259
-
Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther. 2013 Jul; 14(7):638-47.
Score: 0.051
-
Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma--case report. Clin Neurol Neurosurg. 2013 May; 115(5):632-5.
Score: 0.048
-
The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. J Neurosurg. 2010 Aug; 113(2):225-33.
Score: 0.042
-
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. J Neurooncol. 2009 Jun; 93(2):279-83.
Score: 0.038
-
Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res. 2019 04 01; 25(7):2305-2313.
Score: 0.019
-
Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Rep. 2017 01; 18(1):150-168.
Score: 0.016